cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Surface Oncology Inc
12 own
12 watching
Current Price
$0.97
$0
(0.15%)
logo-surf
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
58.82M
52-Week High
52-Week High
3.81
52-Week Low
52-Week Low
0.6024
Average Volume
Average Volume
0.16M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
26.344
iconMarket Capitalization58.82M
icon52-Week High3.81
icon52-Week Low0.6024
iconAverage Volume0.16M
iconDividend Yield--
iconP/E Ratio26.344
What does the Surface Oncology Inc do?
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Surface Oncology Inc make?
News & Events about Surface Oncology Inc.
Globe Newswire
24days ago
Surface Oncology initiates clinical trial with antibody discovered using Vaccinexs ActivMAb Antibody Discovery PlatformROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and ...
Globe Newswire
28days ago
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial clinical data anticipated in 2024 CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ...
Globe Newswire
2 months ago
Data further support SRF388 and SRF114 clinical development programsCAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the ...
PR Newswire
7 months ago
Thinking about buying stock in Inspira Technologies, Annovis Bio, Tenneco, Benitec Biopharma, or Surface Oncology? Thinking about buying stock in Inspira Technologies, Annovis Bio, Tenneco, Benitec Biopharma, or Surface Oncology? PR Newswire NEW YORK, July 7, 2022 NEW YORK, July 7, 2022...
Globe Newswire
7 months ago
- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer - CAMBRIDGE, Mass., June 20, 2022 (GLOBE NEWSWIRE) -- Surface Oncology(Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the ...
Frequently Asked Questions
Frequently Asked Questions
What is Surface Oncology Inc share price today?
plus_minus_icon
Can Indians buy Surface Oncology Inc shares?
plus_minus_icon
How can I buy Surface Oncology Inc shares from India?
plus_minus_icon
Can Fractional shares of Surface Oncology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Surface Oncology Inc stocks?
plus_minus_icon
What is today’s traded volume of Surface Oncology Inc?
plus_minus_icon
What is today’s market capitalisation of Surface Oncology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Surface Oncology Inc?
plus_minus_icon
What percentage is Surface Oncology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Surface Oncology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.97
$0
(0.15%)
logo-surf
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$1.12
$-0.01 (-0.88 %)
IMMUNIC INC
IMMUNIC INC
$2.57
$0.05 (1.98 %)
Passage Bio Inc
Passage Bio Inc
$1.56
$0.07 (4.70 %)
I-Mab
I-Mab
$6.14
$-0.17 (-2.69 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$1.12
$-0.01 (-0.88 %)
IMMUNIC INC
IMMUNIC INC
$2.57
$0.05 (1.98 %)
Passage Bio Inc
Passage Bio Inc
$1.56
$0.07 (4.70 %)
I-Mab
I-Mab
$6.14
$-0.17 (-2.69 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00